Eloxx Pharmaceuticals, Inc. SEC filings ELOX
Eloxx Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Dec 23, 2008. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14C | Information statement | May 8, 2026 | May 8, 2026 |
| PRE 14C | Filing | Apr 28, 2026 | Apr 28, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 22, 2023 |
| DEF 14A | Proxy statement | Oct 31, 2022 | Nov 30, 2022 |
| PRE 14A | Preliminary proxy statement | Oct 17, 2022 | Nov 30, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Apr 1, 2021 | — |
| DEF 14A | Proxy statement | Apr 1, 2021 | May 19, 2021 |
| DEFA14A | Additional proxy material | Apr 1, 2020 | — |
| DEF 14A | Proxy statement | Apr 1, 2020 | May 20, 2020 |
| DEFA14A | Additional proxy material | Apr 5, 2019 | — |
| DEF 14A | Proxy statement | Apr 5, 2019 | May 29, 2019 |
| DEF 14A | Proxy statement | Apr 16, 2018 | May 16, 2018 |
| DEF 14C | Information statement | Mar 30, 2018 | Mar 30, 2018 |
| DEF 14A | Proxy statement | Nov 17, 2017 | Dec 7, 2017 |
| PRE 14A | Preliminary proxy statement | Nov 6, 2017 | Nov 6, 2017 |
| DEF 14A | Proxy statement | Oct 28, 2014 | Dec 15, 2014 |
| DEF 14A | Proxy statement | Jan 6, 2014 | Feb 11, 2014 |
| DEF 14A | Proxy statement | Jul 17, 2013 | Aug 22, 2013 |
| PRE 14A | Preliminary proxy statement | Jul 3, 2013 | Jul 3, 2013 |
| DEFA14A | Additional proxy material | Mar 5, 2013 | — |
| DEF 14A | Proxy statement | Feb 26, 2013 | Mar 28, 2013 |
| PRE 14A | Preliminary proxy statement | Feb 14, 2013 | Feb 14, 2013 |
| DEF 14A | Proxy statement | Nov 1, 2011 | Dec 16, 2011 |
| PRE 14A | Preliminary proxy statement | Oct 18, 2011 | Oct 18, 2011 |
| DEF 14A | Proxy statement | Feb 11, 2011 | Mar 11, 2011 |
| DEF 14A | Proxy statement | Apr 26, 2010 | May 25, 2010 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2010 | Apr 13, 2010 |
| DEFA14A | Additional proxy material | Apr 5, 2010 | — |
| DEF 14A | Proxy statement | Aug 11, 2009 | Sep 22, 2009 |
| PRE 14A | Preliminary proxy statement | Jul 30, 2009 | Jul 30, 2009 |
| DEFA14A | Additional proxy material | Jul 30, 2009 | — |
| DEFA14A | Additional proxy material | Jul 10, 2009 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELOX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1035354
- Former names
- Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.